TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02420457

Intervention type: PROCEDURE
Intervention: Epidural injection
Description: After evaluation by their pain physician, if the clinician offers an epidural injection for their back pain, they will be followed for this study before and after the injection.

Intervention type: DRUG
Intervention: Epidural steroid injection as determined by routine care provider
Description: Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
Study: NCT04308538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Recession
Description: Bilateral lateral rectus muscle recession will be performed through fornix approach using standard tables

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced Recession
Description: Bilateral lateral rectus muscle recession will be performed through fornix approach using reduced numbers
Study: NCT04131283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.
Study: NCT03473873

Intervention type: OTHER
Intervention: Measures of muscle function
Description: The participants will be assessed with various measures of muscle function at baseline and at follow up including: Isokinetic knee muscle strength, Isometric strength of trunk and lower extremity, single-leg hop for distance (SLHD), side hop, postural orientation errors (single leg-squat, stair descending, forward lunge, SLHD), hip and ankle range of motion, and muscular activation patterns.
Study: NCT01457248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube TaperGuard
Description: Patients are intubated by endotracheal tube with taper-shaped cuff (TaperGuard, Mallinckrodt)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube Hi-Contour Brandt
Description: Patients are intubated by endotracheal tube with cylindrical-shaped cuff (Hi-Contour Brandt, Mallinckrodt)
Study: NCT04372264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
Study: NCT00646893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preimplantation Genetic Diagnosis (PGD)
Description: one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by no result rescue (Colls et al. 2007)
Study: NCT02224950

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-medicated Emollient plus Lyocell/Chitosan Sleeve

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-medicated Emollient plus Cotton Sleeve

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sleeve
Study: NCT00768560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat CR, BAYA1040) 80mg OD
Description: Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat CR, BAYA1040) 40mg BID
Description: Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (Adalat CR, BAYA1040) 40mg OD
Description: Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
Study: NCT01215084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB041 (Fampridine-PR)
Description: A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB041 (Fampridine-PR)
Description: A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB041 (Fampridine-PR)
Description: A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants
Study: NCT02015819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli CD-expressing genetically modified neural stem cells
Description: Given intracranially

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flucytosine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02643758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bifocal soft contact lenses
Study: NCT02856126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE regimen
Description: infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC Regimen
Description: Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Sorafenib
Description: Oral Sorafenib, 400mg, Bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sorafenib
Description: Oral Sorafenib, 400mg, Bid
Study: NCT01393028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Description: Cardiac CT: calcium scan and CT coronary angiography

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care according to international guidelines
Study: NCT02015819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02473406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha 1
Description: In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
Study: NCT04054063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486+ etomidate
Study: NCT02473406

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
Study: NCT02489461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz up to 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral therapy (ART)
Description: Antiretroviral therapy up to 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Description: Antiretroviral therapy up to 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Description: Antiretroviral therapy up to 96 weeks
Study: NCT01373593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01055041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled budesonide and formeterol plus oral montelukast
Description: 1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled budesonide and formeterol plus oral doxophylline
Description: 1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
Study: NCT02906228

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
Study: NCT00918450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed
Study: NCT02232698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor Based Glucose Monitoring System
Description: Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Blood Glucose Monitoring
Description: Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study (Sensor glucose measurements not visible during this time).~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time).
Study: NCT03869437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: 2 grams intravenously administered over 3 hours every 8 hours for a period of 5 to 14 days (dosage adjustment is necessary based on renal function).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Standard of care was determined by the investigator
Study: NCT00387127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib oral tablets
Description: Lapatinib is administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lapatinib oral tablets
Description: Lapatinib is administered orally once daily.
Study: NCT01055041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doubling the dose of inhaled budesonide and formeterol
Description: 1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
Study: NCT03265574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
Study: NCT04042285

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shockwave therapy
Description: Extracorporeal shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second. Participants will receive 3 sessions of shockwave therapy in a 7-day period.
Study: NCT03263026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzastaurin Hydrochloride
Description: R-CHOP + Enzastaurin (Kinenza®) 125 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: R-CHOP + placebo
Description: R-CHOP + placebo
Study: NCT01272154

Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (PAS and rTMS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (PAS and rTMS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (PAS and rTMS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (PAS and rTMS)
Study: NCT02610712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study: NCT03671681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The experimental group will receive education, will be prescribed prophylaxis and will attend Mindfulness-based therapy sessions. The MINDFULNESS therapy consists in 6 weekly sessions, 45 minutes each. The main focus of the six mindfulness session will be the following: 1) introduction and meaning; 2) Focus on breath; 3) posture and body awareness; 4) meditation of sounds; 5) Guided imagery; 6) acceptance and awareness. During training, patients will be invited to close their eyes, assume a relaxed position, focus on their breathing and on the present to enhance awareness of current mind and body sensations. Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.

Intervention type: DRUG
Group type: OTHER
Intervention: Prophylactic
Description: Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic
Description: Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
Study: NCT00387127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
Study: NCT02217943

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Study: NCT06789354

Intervention type: OTHER
Intervention: Questionnaire and Physical Exam
Description: All assessments were carried out face-to-face with the same physiotherapist.
Study: NCT02253251

Intervention type: GENETIC
Intervention: KRAS-variant and microRNA binding site mutation testing
Description: Participant in these studies will be tested for the KRAS-variant
Study: NCT00387127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin chemotherapy
Description: Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
Study: NCT02253251

Intervention type: GENETIC
Intervention: KRAS-variant and microRNA binding site mutation testing
Description: Participant in these studies will be tested for the KRAS-variant

Intervention type: GENETIC
Intervention: KRAS-variant and microRNA binding site mutation testing
Description: Participant in these studies will be tested for the KRAS-variant

Intervention type: GENETIC
Intervention: KRAS-variant and microRNA binding site mutation testing
Description: Participant in these studies will be tested for the KRAS-variant
Study: NCT00387127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin chemotherapy
Description: Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
Study: NCT04008368

Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACS CD34 Reagent
Description: Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.

Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACS CD34 Reagent
Description: Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.
Study: NCT02818257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strip A
Description: Adhesive strip A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strip A
Description: Adhesive strip A
Study: NCT04042285

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Wound Care
Description: dressing changes, negative pressure wound therapy, offloading footwear, debridement, glycaemic control and antibiotics as necessary
Study: NCT03325387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT01561391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Infused continuously at 50 mcg/kg/hr through Day 5 then at 25 mcg/kg/hr on Days 6 to10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Injected every 2 hours during surgery through Day 5, then every 4 hours for Days 6 to 10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: factor IX
Description: Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: factor VIII
Description: Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
Study: NCT03375047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRT5005
Description: Nebulization of MRT5005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRT5005
Description: Nebulization of MRT5005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRT5005
Description: Nebulization of MRT5005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRT5005
Description: Nebulization of MRT5005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRT5005
Description: Nebulization of MRT5005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRT5005
Description: Nebulization of MRT5005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline for Inhalation
Study: NCT00647686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay
Description: single application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Transdermal System 25 mcg/h
Description: single application
Study: NCT03699696

Intervention type: DRUG
Intervention: Propofol
Description: Induction of anesthesia prior to surgery with propofol

Intervention type: DRUG
Intervention: Propofol
Description: Induction of anesthesia prior to surgery with propofol

Intervention type: DRUG
Intervention: Propofol
Description: Induction of anesthesia prior to surgery with propofol
Study: NCT04548778

Intervention type: DIAGNOSTIC_TEST
Intervention: BÜHLMANN fPELA assay
Description: BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: BÜHLMANN fPELA assay
Description: BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
Study: NCT01921894

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.
Study: NCT03351998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipitor 20Mg Tablet
Description: 20 mg/day pills.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipitor 80Mg Tablet
Description: 80 mg/day pills.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching placebo pill.